A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

PHASE1RecruitingINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

June 8, 2022

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Interventions
DRUG

LY3849891

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (16)

32751

RECRUITING

Accel Research Sites - Maitland, Maitland

32803

RECRUITING

Charter Research - Winter Park, Orlando

33016

RECRUITING

Floridian Clinical Research, Miami

33122

RECRUITING

Evolution Clinical Trials, Inc, Miami

33175

RECRUITING

Advanced Pharma Clinical Research, Miami

33511

RECRUITING

Synergy Healthcare LLC, Brandon

46290

RECRUITING

IU Health University Hospital, Indianapolis

77079

RECRUITING

Houston Research Institute, Houston

78229

RECRUITING

Clinical Trials of Texas, Inc., San Antonio

RECRUITING

Pinnacle Clinical Research, San Antonio

85225

RECRUITING

Arizona Liver Health - Chandler, Chandler

92377

RECRUITING

Inland Empire Clinical Trials, LLC, Rialto

92868

RECRUITING

Orange County Research Center, Orange

192-0071

RECRUITING

P-One Clinic, Hachiōji

160-0004

RECRUITING

Clinical Research Hospital Tokyo, Shinjuku-ku

00927

RECRUITING

FDI Clinical Research, San Juan

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY